B-Cell-Directed Therapies in Systemic Lupus Erythematosus

Seminars in Arthritis and Rheumatism

Volumn 38, Issue 3, 2008, Pages 218-227

  Tieng, Arlene T ^a   Peeva, Elena ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

B cells; monoclonal antibodies; systemic lupus erythematosus; treatment

Indexed keywords

ABATACEPT; ABETIMUS; ANTIHISTAMINIC AGENT; ATLIZUMAB; B N10; BELIMUMAB; BG 9588; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; DOUBLE STRANDED DNA ANTIBODY; EPRATUZUMAB; GLUCOCORTICOID; IMMUNOLOGIC AGENT; IMMUNOSUPPRESSIVE AGENT; MEDI 545; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG;

ABSCESS; ABSENCE OF SIDE EFFECTS; ACUTE GASTROENTERITIS; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BACTEREMIA; BELL PALSY; BRADYCARDIA; BRONCHITIS; CARDITIS; CELLULITIS; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INFUSION REACTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLICULITIS; GASTRITIS; GASTROENTERITIS; HEART INFARCTION; HEMATURIA; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MIGRAINE; MONOTHERAPY; NAUSEA; NECROTIZING FASCIITIS; NEPHRITIS; NONHODGKIN LYMPHOMA; PAROTID GLAND ABSCESS; PLEURISY; PRIORITY JOURNAL; PYELONEPHRITIS; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SOMNOLENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; THROMBOPHLEBITIS; THRUSH; TINEA PEDIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URTICARIA;

B-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 54049138278     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.11.003     Document Type: Article

References (69)

1. Browning J. B-cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5 (2006) 564-576
2. Sims G., Ettinger R., Shirota Y., Yarboro C.H., Illei G.G., and Lipsky P.E. Identification and characterization of circulating human transitional B cells. Blood 105 (2005) 4390-4398
3. Hutloff A., Buchner K., Reiter K., Baelde H.J., Odendahl M., Jacobi A., et al. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 50 (2004) 3211-3220
4. Wei C., Anolik J., Cappione A., Zheng B., Pugh-Bernard A., Brooks J., et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 178 (2007) 6624-6633
5. Bhat N.M., Lee L.M., van Vollenhoven R.F., Teng N.N., and Bieber M.M. VH4-34 encoded antibody in systemic lupus erythematosus: effect of isotype. J Rheumatol 29 (2002) 2114-2121
6. Cappione A., Anolik J.H., Pugh-Bernard A., Barnard J., Dutcher P., Silverman G., et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 115 (2005) 3205-3216
7. Looney R. B cells as a theurapetic target in autoimmune disease other than rheumatoid arthritis. Rheumatology 44 suppl 2 (2005) ii13-ii17
8. Edwards J., and Cambridge G. Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) 44 (2005) 151-156
9. Kalunian K., Davis Jr. J.C., Merrill J.T., Totoritis M.C., Wofsy D., and IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 3251-3258
10. Boumpas D., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., et al., BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48 (2003) 719-727
11. Furie R., Stohl W., Ginzler E., Becker M., Mishra N., Chatham W., et al. Safety: Pharmacokinetics and pharmacodynamic results of a phase 1 single and double dose-escalation study of lymphostat-B (human monoclonal antibody to BlyS) in SLE patients. Arthritis Rheum 48 suppl (2003) S377 (Abstract)
12. Mosca M., Baldini C., and Bombardieri S. LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. Exp Opin Pharmacother 8 (2007) 873-879
13. Lacki J., Samborski W., and Mackiewicz S.H. Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Clin Rheumatol 16 (1997) 275-278
14. Illei G., Yarboro C., Shirota Y., Tackey E., Lapteva L., Fleisher T., et al. Tocilizumab (Humanized Anti IL-6 Receptor Monoclonal Antibody) in patients with systemic lupus erythematosus (SLE): safety, tolerability and preliminary efficacy. Arthritis Rheum 54 suppl (2006) 4043 (Abstract)
15. Llorente L., Zou W., Levy Y., Richaud-Patin Y., Wijdenes J., Alcocer-Varela J., et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181 (1995) 839-844
16. Gopal A., and Press O.W. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 134 (1999) 445-450
17. Nitschke L., Carsetti R., Ocker B., Kohler G., and Lamers M.C. CD22 is a negative regulator of B-cell receptor signaling. Curr Biol 7 (1997) 133-143
18. Dass S., Vital E.M., and Emery P. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Exp Opin Pharmacother 7 (2006) 2559-2570
19. Dorner T., Kaufmann J., Wegener W., Teoh N., Goldenberg D., and Burmester G. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8 (2006) R74
20. Leandro M., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46 (2002) 2673-2677
21. Leandro M., Ehrenstein M.R., Edwards J.C.W., Manson J., Cambridge G., and Isenberg D.A. Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum 48 suppl (2003) S378 (Abstract)
22. Leandro M., Edwards J.C., Ehrenstein M.R., Cambridge G., and Isenberg D.A. B lymphocyte depletion in the treatment of systemic lupus erythematosus. Arthritis Rheum 50 suppl (2004) S447 (Abstract)
23. Leandro M., Cambridge G., Edwards J.C., Ehrenstein M.R., and Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44 (2005) 1542-1545
24. Looney R., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell deletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalating trial of rituximab. Arthritis Rheum 50 (2004) 2580-2589
25. Albert D., Kahn S.R., Stansberry J., Tsai D., and Eisenberg R.A. A phase I trial of rituximab for treatment of systemic lupus erythematosus. Arthritis Rheum 50 suppl (2004) S446 (Abstract)
26. Smith K., Jones R.B., Burns S.M., and Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 54 (2006) 2970-2982
27. Tanaka Y., Yamamoto K., Takeuchi T., Nishimoto N., Miyasaka N., Sumida T., et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Arthritis Rheum 54 suppl (2006) S258 (Abstract)
28. Kneitz C., Wilhelm M., and Tony H.P. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 206 (2002) 519-527
29. US National Institutes of Health. A study to evaluate the efficacy and safety of rituximab in patients with severe systemic lupus erythematosus (SLE) [online]. [Accessed 2007 Feb 28]. http://www.clinicaltrials.gov/ct/show/NCT00137969?order=2
30. US National Institutes of Health. A study to evaluate rituximab in subjects with ISN/RPS class III or IV lupus nephritis (LUNAR) [online]. [Accessed 2007 Feb 28]. http://clinicaltrials.gov/ct/show/NCT00282347?order=1
31. Dorner T., Kaufmann J., Wegener W.A., Teoh N., Goldenberg D.M., and Burmester G.R. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8 (2006) R74
32. US National Institutes of Health. Study of Epratuzumab in Systemic Lupus Erythematosus [online]. [Accessed 2007 Feb 28]. http://clinicaltrials.gov/ct/show/NCT00382837?order=1
33. Jones D., Hachmann J.P., Osgood S.A., Hayag M.S., Barstad P.A., Iverson G.M., et al. Conjugates of double-stranded oligonucleotides with poly(ethylene glycol) and keyhole limpet hemocyanin: a model for treating systemic lupus erythematosus. Bioconjug Chem 5 (1994) 390-399
34. Alarcon-Segovia D., Tumlin J.A., Furie R.A., McKay J.D., Cardiel M.H., Strand V., et al., LJP 394 Investigator Consortium. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 48 (2003) 442-454
35. Furie R., Cash J.M., Cronin M.E., Katz R.S., Weisman M.H., Aranow C., et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 28 (2001) 257-265
36. US National Institutes of Health. Study of LJP 394 in Lupus Patients With History of Renal Disease [online]. [Accessed 2007 April 27]. http://clinicaltrials.gov/ct/show/NCT00089804?order=3
37. Grammer A., Slota R., Fischer R., Gur H., Girschick H., Yarboro C., et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 112 (2003) 1506-1520
38. US National Institutes of Health. Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis [online]. [Accessed 2007 Mar 1]. http://www.clinicaltrials.gov/ct/gui/show/NCT00430677?order=45
39. Gross J., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 (2000) 995-999
40. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190 (1999) 1697-1710
41. Stohl W., Metyas S., Tan S.M., Cheema G.S., Oamar B., Xu D., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 48 (2003) 3475-3486
42. Stohl W. SLE-systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther 5 (2003) 136-138
43. Wallace D., Lisse J., Stohl W., McKay J., Boling E., Merrill J.T., et al. Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks. Arthritis Rheum 54 suppl (2006) S790 (Abstract)
44. US National Institutes of Health. A Study of Belimumab, a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) [online]. [Accessed 2007 Mar 1]. http://www.clinicaltrials.gov/ct/gui/show/NCT00410384?order=1
45. Cross J., and Benton H. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm Res 48 (1999) 255-261
46. Llorente L., Richaud-Patin Y., Garcia-Padilla C., Claret E., Jakez-Ocampo J., Cardiel M.H., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43 (2000) 1790-1800
47. Nishimoto N., and Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2 (2006) 619-626
48. Lee P., and Reeves W.H. Type I interferon as a target of treatment in SLE. Endocr Metab Immune Disord Drug Targets 6 (2006) 323-330
49. Niewold T., and Swedler W.I. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 24 (2005) 178-181
50. Crow M., Kirou K., and Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36 (2003) 481-490
51. Baechler E., Gregersen P., and Behrens T. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 16 (2004) 801-807
52. Medical News Today. Accessed April 24, 2007. MedImmune Begins Dosing of Lupus Patients In Phase 1 Clinical Trial [press release]. Available at: http://www.medicalnewstoday.com/medicalnews.php?newsid=41611.
53. Sfikakis P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52 (2005) 501-513
54. Vallerskog T., Heimbürger M., Gunnarsson I., Zhou W., Wahren-Herlenius M., Trollmo C., et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 8 (2006) R167
55. D'Arcy C., and Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 44 (2001) 1717-1718
56. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol 70 (2002) 329
57. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52 (2005) 2740-2750
58. Zecca M., Nobili B., Ramenghi U., Perrotta S., Amendola G., Rosito P., et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101 (2003) 3857-3861
59. Binstadt B., Caldas A.C., and Turvery S.E. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr 143 (2003) 598-604
60. Marks S., Patey S., Brogan P.A., Hasson N., Pilkington C., Woo P., et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52 (2005) 3168-3174
61. Nakahara H., and Nishimoto N. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases. Endocr Metab Immune Disord Drug Targets 6 (2006) 373-381
62. Calvani N., Tucci M., Richards H., Tartaglia P., and Silvestris F. Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun Rev 4 (2005) 542-548
63. Boackle S. Role of complement receptor 2 in the pathogenesis of systemic lupus erythematosus. Adv Exp Med Biol 560 (2005) 141-147
64. Carroll M. The role of complement in B cell activation and tolerance. Adv Immunol 74 (2000) 61-88
65. Baker K. BLyS-an essential survival factor for B cells: basic biology, links to pathology and therapeutic target. Autoimmun Rev 3 (2004) 368-375
66. Carter R., Zhao H., Liu X., Pelletier M., Chatham W., Kimberly R., et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 52 (2005) 3943-3954
67. Okazaki T., and Wang J. PD-1/PD-L pathway and autoimmunity. Autoimmunity 38 (2005) 353-357
68. Hoi A., Morand E., and Leech M. Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus?. Immunol Cell Biol 81 (2003) 367-373
69. Ishikawa S., and Matsushima K. Aberrant B1 cell trafficking in a murine model for lupus. Front Biosci 12 (2007) 1790-1803